SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy

SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy

Inhibition of the NEDD8-activating enzyme (NAE), the key E1 enzyme in the neddylation cascade, has been considered an attractive anticancer strategy with the discovery of the first-in-class NAE inhibitor, MLN4924. In this study, we identified SOMCL-19-133 as a highly potent, selective, and orally av...

Full description

Bibliographic Details
Main Authors: Li-Na Zhou, Chaodong Xiong, Yong-Jun Cheng, Shan-Shan Song, Xu-Bin Bao, Xia-Juan Huan, Tong-Yan Wang, Ao Zhang, Ze-Hong Miao, Jin-Xue He
Format: Article
Language:English
Published: Elsevier 2022-10-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
SOMCL-19-133
NAE inhibitor
MLN4924
NEDD8
Oral administration
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558622000501

Internet

http://www.sciencedirect.com/science/article/pii/S1476558622000501

Similar Items